

Enteric Toxins from Bacteria Colonizing Human Gut

Gianfranco Donelli¹, Loredana Falzano¹, Alessia Fabbri¹, Carla Fiorentini¹ and Paola Mastrantonio²

From the ¹Laboratory of Ultrastructures and ²Laboratory of Bacteriology and Medical Microbiology, Istituto Superiore di Sanità, Rome, Italy

Correspondence to: Professor Gianfranco Donelli, Istituto Superiore di Sanità Viale Regina Elena, 299 00161 Rome, Italy. Fax + 39 06 49387140; E-mail: donelli@iss.it

Microbial Ecology in Health and Disease 2000; Suppl 2: 194–208

The large and heterogeneous microbial population colonising the human intestinal tract includes a number of aerobic and anaerobic bacteria that produce one or more toxins. While exhibiting very different physico-chemical properties these exotoxins share the ability to penetrate intestinal cells after their binding to a specific surface receptor, thus reaching a subcellular target at membrane or cytoskeleton level. The most relevant *in vitro* and *in vivo* data, reported in the literature, on the mode of action of the major enterotoxins and cytotoxins produced by bacteria belonging to the human gut microflora are reviewed in the light of our recent knowledge on bacteria-host cell interactions.

INTRODUCTION

Intraluminal flora of the intestinal tract forms an extremely large and heterogeneous microbial ecosystem including aerobic, microaerophilic and strictly anaerobic bacteria. The small intestine represents a transition area between the scarcely colonised stomach and the abundant colonic flora, normally reaching in healthy subjects 10^{11} colony forming units/mg of intestinal content. In fact, a third of the faecal dry weight consists in bacteria, the anaerobes outnumbering the aerobic species by a hundred to ten thousand times.

Among the numerous extracellular products, exotoxins produced and released from bacteria belonging to the normal gut microflora appear to be potent weapons whose possible harmful effects on the intestinal mucosa deserve in our opinion wider attention. Even more by the light of the increasing amount of *in vitro* and *in vivo* results obtained in recent years on their mode of action. These toxins are very heterogeneous as far as their physico-chemical properties and bacterial sources are concerned, being produced by anaerobic (*Bacteroides fragilis*, *Clostridium difficile*, *Clostridium perfringens*) and aerobic (*Enterococcus faecalis*, *Escherichia coli*, *Staphylococcus aureus*) species (Table I). However, this group of toxins shares the ability of penetrating animal cells after binding to a specific receptor present on the cell surface, thus reaching an intracellular target at membrane and/or cytoskeletal level.

In fact, recent studies on different mammalian cell lines indicate the microfilaments, constituted by the 42 kDa G-actin and several actin binding proteins, as the primary

targets for an increasing number of toxins (1–6) produced by enteric bacteria. Recalling the significant role of the actin cytoskeleton in numerous cellular functions (7–11) and the participation of actin as the main constituent in the intestinal brush border cytoskeleton, the direct or indirect role of these toxins as proinflammatory agents and virulence factors needs to be further elucidated. In this regard a review of the most relevant data available so far on the main features and the mode of action of the major enterotoxins and cytotoxins produced by enteric bacteria colonising the human intestinal tract (12) may be of value in identifying unclear aspects, missing data and future research targets.

BACTEROIDES FRAGILIS TOXIN (BFT)

Bacteroides fragilis is an obligately anaerobic bacterium that is part of the normal colonic flora (13). Despite accounting for only about 1% of 10^{11} organisms/g of stool, *B. fragilis* is the obligate anaerobe most frequently isolated from patients with intraabdominal abscesses and bloodstream infections. However, neither diarrhoeal disease nor extracellular toxin production due to *B. fragilis* was appreciated until 1984. In fact, the initial suggestion that *B. fragilis* could be a cause of diarrhoea came from studies of diarrhoeal disease in lambs in which Myers and his colleagues (14) noted that stools from diarrhoeic lambs were able to stimulate a secretory response in ligated intestinal loops in healthy lambs. In a series of experiments involving cultures on various media and serial passage of strains in lamb ligated intestinal loops, it was determined that the

secretory response observed could be attributed only to an obligate anaerobe which was identified as being *B. fragilis*. By experimental inoculation of lambs with the secretion-producing strains of *B. fragilis*, clinical signs of the natural disease were reproduced, whereas with strains that were nonsecretory in lamb ligated intestinal loops no signs of disease were found. Further studies demonstrated that culture filtrates of the pathogenic *B. fragilis* strains, but not of the control *B. fragilis* strains, concentrated 20-fold, also stimulated a secretory response in lamb ligated intestinal loops at 18 hours but not before 6 hours (15). Notably, loops treated for > 18 hours with concentrated culture filtrates tended to burst, an indication of the potency of the secretory response. On the basis of these observations, strains that stimulate secretion in lamb ligated intestinal loops have been termed *enterotoxigenic B. fragilis* (ETBF).

The fluid response was dependent on the animal model used. In fact, in the ileum this response was greater in lambs than in rabbits and rats, whereas the fluid response in the colon was greater in rabbits than in lambs and rats. Analysis of the intestinal fluid elicited by the enterotoxin revealed an accumulation of sodium and chloride as well as albumin and total protein. After histological examination mild necrosis of epithelial cells, crypt elongation, villus attenuation, and hyperplasia were revealed. Moreover, there was an extensive detachment and rounding of surface epithelial cells as well as an infiltration of neutrophils (16).

Several studies suggest that the intestinal effects of *B. fragilis* are attributable to a protein toxin (17). This toxin is an extracellular heat-labile protein with an estimated molecular weight of about 20000 Da as determined by gel filtration chromatography on Superose-12 and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The purified toxin is stable at -20°C and 4°C and upon freeze-drying, but it is unstable at temperatures above 55°C . It is characterised by an isoelectric point of approximately 4.5 and is stable at pHs between 5 to 10. It is resistant to trypsin and chymotrypsin but is sensitive to proteinase K and *Streptomyces* protease (18). Like culture filtrates of ETBF, the purified toxin stimulates fluid accumulation in lamb ligated ileal loops and alters the morphology of intestinal epithelial cells *in vitro* as well. Both of these biological activities are neutralised by monospecific antisera to the purified toxin. The amino acid sequence revealed a zinc-binding consensus motif signature (HEXXHXXGXXH/Met-turn) characteristic of metalloproteases termed metzincins (19) and the sequence comparison shows high identity to matrix metalloproteases (e.g., human fibroblast collagenase) within the zinc-binding and Met-turn region. One g-atom of Zn^{2+} per molecule is contained in the purified enterotoxin and it is capable of hydrolysing gelatin, azocoll, actin, tropomyosin, and fibrinogen. Moreover, the enterotoxin is capable of undergoing autodigestion. Optimal proteolytic activity occurs at

Table I

Bacteria colonising human gut and their major enteric toxins

Bacterium	Toxins	MW	Mode of action
<i>Bacteroides fragilis</i>	BFT	20 kDa	Cytotoxic and enterotoxic
<i>Clostridium difficile</i>	Tox A	308 kDa	Cytotoxic and enterotoxic Pro-apoptotic
	Tox B	270 kDa	Cytotoxic Pro-apoptotic
<i>Clostridium perfringens</i>	Enterotoxin	35 kDa	Enterotoxic and cytotoxic Pore-former
<i>Enterococcus faecalis</i>	Cytolysin		Acting both as a haemolysin toxic to eukaryotic cells and as a bacteriocin active against gram-positive bacteria Enterotoxic?
<i>Escherichia coli</i>	CDTs	76 kDa	Inhibitor of cell division
	CNFs	110 kDa	Cytotoxic and dermonecrotic Anti-apoptotic
	LTs	85 kDa	Enterotoxic
	STs	2 kDa	Enterotoxic
<i>Staphylococcus aureus</i>	SEA		Enterotoxic, superantigen, indirectly pro-apoptotic via T-cell activation and cytokine secretion
	SEB		
	SEC1		
	SEC2	22–29 kDa	
	SEC3		
	SED		
SEE			
	Delta-toxin	3 kDa	Cytolytic Pore-former Enterotoxic?

37°C and pH 6.5. Primary proteolytic cleavage sites in actin have been identified, revealing cleavage at Gly-Met and Thr-Leu peptide bonds. Enzymatic activity is inhibited by metal chelators but not by inhibitors of other classes of proteases. Additionally, both, the cytotoxic and enterotoxic activity is inhibited by the metal chelators such as EDTA and 1,10-phenanthroline.

Two isoforms of *B. fragilis* toxin (BFT) have been isolated, one secreted by the lamb (ETBF strain VPI 13784) and the second by the piglet (ETBF strain 86-5443-2-2). Nucleotide sequence analysis studies revealed 92% identity and 95% similarity in the amino acid sequences of these two isoforms of BFT. Based on their biochemical properties, these isoforms represent two distinct proteins and are therefore termed BFT-1 (strain VPI 13784) and BFT-2 (strain 86-5443-2-2). However, the biological activities of these two proteins are very similar. The *bft* gene from ETBF strain 86-5443-2-2 consists of one open reading frame of 1,91 nucleotides encoding a predicted 397-residue holotoxin with a calculated molecular weight of 44,493 Da. BFT is most probably synthesised as a pre-protein by ETBF strains as the comparison of the predicted BFT protein sequence with the N-terminal amino acid sequence of purified BFT indicates. These data suggest that BFT is processed to yield a biologically active toxin of 186 residues with a molecular mass of about 20 kDa which is secreted into the culture supernatant. In fact, analysis of the holotoxin sequence predicts a 20-residue amphipathic region at the carboxy terminus of BFT (20, 21). Comparison of the sequences available for the *bft* genes from ETBF 86-5443-2-2 and VPI 13784 revealed two regions of reduced homology.

Hybridisation of oligonucleotide probes specific for each *bft* with toxigenic *B. fragilis* strains revealed that 51 and 49% of toxigenic strains contained the 86-5433-2-2 and VPI 13784 *bft* genes, respectively. No toxigenic strain hybridised with both probes. These two subtypes have been termed *bft* 1 (VPI 13784) and *bft*-2 (86-5433-2-2).

The BFT is detectable (22) by morphological changes on HT29, T84, and Caco-2 cells, continuous intestinal epithelial cell lines derived from human colonic carcinomas. The toxin does not alter the morphology of Chinese hamster ovary (CHO), Y-1 adrenal, or MDCK cells, all of which are nonintestinal cell lines (23). Numerous studies have been performed on HT29/C1 cells, which represent a suitable model for studying the TBF and it constitutes an established cytotoxic assay used to detect enterotoxigenic *B. fragilis* (24). After treatment with crude or purified BFT, cells become rounded with numerous surface blebs and the cell clusters dissociate within 3 hours (25, 26). Such alterations in HT29 cells are completely reverted 24 h after the addition of the toxin (27). Experiments with purified toxin reveal that subconfluent HT29/C1 cells treated with as little as 0.1 ng of purified toxin/ml (5 pM) develop morphological changes. Furthermore, staining of

toxin-treated HT29/C1 cells with rhodamine-phalloidin, which specifically binds to filamentous actin (F-actin), reveals dissociation of F-actin after toxin treatment that is consistent with the BFT altering the cytoskeleton of intestinal epithelial cells. In fact, typical effects are the redistribution of F-actin, which become completely marginalised, and the loss of stress fibres, the filamentous and contractile form of actin (27). BFT acts also on cell volume and this response is persistent and dependent on the proteolytic activity of BFT. Intoxicated cells exhibit regulatory volume decrease, suggesting that toxin-treated cells remain physiologically dynamic.

For further assessment of the effect of crude and purified toxin on the physiology of intestinal epithelial cells *in vitro*, HT29/C1, Caco-2, or T84 cells were used for studies in Ussing chambers (28, 29). The Ussing chamber is an experimental technique for investigating the physiology of monolayers of cultured intestinal epithelial cells under conditions of ionic, osmotic, and electrical equilibrium. By assessment of three parameters, i.e., short circuit current (I or I_{sc}), potential difference (V or PD) and monolayer resistance (R), changes in active ion transport and monolayer resistance are measured. Under voltage-clamped conditions, I_{sc} and PD are measured; R is calculated by Ohm's law ($V = IR$). The most consistent observation with both crude and/or purified toxin was a striking decrease in monolayer resistance over time. The onset of this decrease typically occurred 20–50 minutes after treatment of apical or basolateral surfaces of the monolayers with toxin. However, the loss of monolayer resistance occurred more quickly and was more complete with toxin application to basolateral surfaces. Depending on the cell line used, in some experiments an increase in I_{sc} that was separable from the calculated changes in monolayer resistance was also observed. This increase in I_{sc} suggests that BFT may also stimulate chloride secretion. These changes in the physiology of HT29/C1 or T84 monolayers occur without release of intracellular lactate dehydrogenase or changes in protein synthesis, thus indicating that cellular damage is not responsible for the loss of monolayer resistance. In addition, T84 monolayers stained with rhodamine-phalloiding showed alteration in F-actin distribution in the cells that may account for the diminished monolayer resistance observed. However, the relationship of the changes in F-actin distribution to the changes in I_{sc} observed in T84 monolayers in response to the ETBF toxin is presently unknown. Although the real contribution of the BFT to the pathogenesis of diarrhoeal disease is yet unknown, it is postulated that this toxin potentially contributes to diarrhoea by altering the barrier function of the intestinal epithelium and by stimulating chloride secretion.

A recent report demonstrates that BFT specifically cleaves E-cadherin within the extracellular domain of the zonula adherens protein. Cleavage of E-cadherin by BFT

is ATP-independent and essential for the morphologic and physiologic activity of BFT. However, the morphologic changes occurring in response to BFT are dependent on target-cell ATP. E-cadherin is, thus, the cellular substrate for a bacterial toxin and this phenomenon represents the identification of a mechanism of action, cell-surface proteolytic activity, for a bacterial toxin (30).

CLOSTRIDIUM DIFFICILE TOXINS

The Gram-positive anaerobic bacterium, *Clostridium difficile*, is the causative agent of pseudomembranous colitis and of most cases of antibiotic-associated diarrhoea (31–40).

There are many virulence factors expressed by pathogenic strains of *C. difficile* and involved in the onset of diarrhoea and colitis, including fimbriae, proteases and toxins (41–51). The most important and best studied since the early 1980s (52–55) are two exotoxins: toxin A, a cytotoxic enterotoxin (56–62) and toxin B, a more potent cytotoxin lacking enterotoxic activity (63, 64). Both toxins belong to the group of intracellularly acting bacterial proteins which have to be internalised via receptor-mediated endocytosis to exert their cytotoxicity.

Toxins A and B are very large single-chain polypeptides having molecular weights of 308 kDa and 270 kDa, respectively. The genes encoding *C. difficile* toxins have been cloned and sequenced (65–69). The two toxins have about 60% homology at the amino acid level and share an identical structural composition. The polypeptides are composed of three functional domains: i) the N-terminal catalytic domain; ii) the intermediate translocation domain; iii) the C-terminal receptor binding domain. The N-terminal region is thought to specify toxin activity and the rather small hydrophobic intermediate part is involved in entry of the toxins into cells. Near the C-terminal domain is a region comprising of CROPS (C-terminal repeated oligopeptides), which might be involved in membrane receptor binding. In toxin A these CROPS act as receptor-binding sites for galactose-containing residues (Gal₁₋₃Gal₁₋₄GlcNAc) on the surface of the intestinal epithelial cells in hamsters and rabbits (70, 71). This is similar to the receptor in the human intestine where I, X and Y antigens in the membranes of epithelial cells lining the mucosa may bind the toxin (72). All these carbohydrate antigens contain the type 2 core (Gal₁₋₄GlcNAc) that appears to be the minimum carbohydrate structure bound by toxin A.

Other common structural features are a hydrophobic region of approximately 50 amino acids in the middle part of the protein and four conserved cysteine residues.

Excellent studies have been performed to investigate the properties of these conserved features by constructing toxin B mutants (73). In particular a significant decrease of cytotoxicity was observed by (i) substituting histidine with

glutamine at the nucleotide-binding site, suggesting that this region could be the active site; and (ii) removing the internal hydrophobic region that may be responsible for processing and internalisation.

Despite their similarities, the biological activities of the toxins differ. Toxin A causes tissue damage and changes in permeability that result in fluid accumulation in rabbit ileal and colonic loops (74, 75). By contrast, in the animal model toxin B shows no effects on permeability or intestinal integrity.

The observation that a mixture of toxin B with low amount of toxin A when given to hamsters provokes their death suggests that toxin B acts synergistically with toxin A and that the latter is needed for initial tissue damage (45).

Only recently was toxin B shown to cause greater damage to human colonic epithelium *in vitro* than toxin A. In fact it has been demonstrated that, like toxin A, toxin B perturbs the cytoskeleton of human colonic cancer T84 cell monolayers causing an increase in transepithelial resistance (64). In addition, toxin B and toxin A have been tested on human colonic mucosa mounted in Ussing chambers (76). The results of this study demonstrated that both toxins cause morphologic damage and dose-dependent electrophysiologic alterations in human colonic mucosa and that toxin B is more effective than toxin A. This is the first line of evidence of the activity of toxin B on an undisturbed mucosa and may represent a different behaviour of the human intestine with respect to the animal models.

It is possible to speculate that the different biological effects of toxins A and B in the animal model (77) are related to the different receptors used by the toxins.

The main common activity of both toxins, the cytotoxicity in cultured cells, even if toxin A is 1000-fold less active than toxin B, has been widely documented and characterised up to the recent determination of the exact mode of action.

In fact, several lines of mammalian cells respond to both toxins although differences in sensitivity can be noted among cell types (78, 79). As viewed by light and scanning electron microscopy, the morphological effect induced by toxins A and B in cell monolayers mainly consists in the retraction and rounding up of the cell body. These morphological changes are generally irreversible and followed by an inhibition of the cell division, but antioxidants are able to protect epithelial cells against the oxidative imbalance due to *C. difficile* toxins (80). Cytoskeleton appears to be strongly involved in such modifications. As observed by fluorescence microscopy, the early response to *C. difficile* toxins is a dramatic change in the microfilament organisation, evident when the cells are still adhering to the substrate (78, 81–88). Prolonging time of exposure, the progressive alteration in the F-actin pattern leads ultimately to the formation of the rounded cells. Protrusions or blebs on the cell surface are also observed by scanning

electron microscopy, the blebbing phenomenon being dose and time dependent (89). These modifications affect the microfilament network of the cytoskeleton without interfering directly with F-actin formation, leading to a relocation of F-actin. The change in F-actin organisation is the earliest visible sign of cellular intoxication and is detectable prior to alteration in the microtubular and intermediate filament networks.

As recently demonstrated, toxins A and B are monoglucosyltransferases which catalyse the incorporation of glucose into the small GTP-binding proteins of the Rho family (90–93).

Three subfamilies belong to the Rho family: Rho, Rac and Cdc42. These are involved in the regulation of the dynamic actin cytoskeleton (7). Each of them, however, regulates distinct structures: Rho governs the formation of stress fibres and focal adhesions, Rac is involved in membrane ruffling and Cdc42 in the formation of filopodia. The best understood functional module is the formation of the stress fibres: Rac and Rho regulate the phosphatidylinositol 4-phosphate-5-kinase to form PIP₂, which stimulates actin polymerisation and filament growth through interaction with several actin-binding proteins (e.g. gelsolin, profilin). The stress fibres, a supraorganisation of actin filaments, are governed by the RhoA-dependent Rho-Kinase which phosphorylates the myosin light chain thereby activating the actin-myosin system in non-muscle cells. The membrane attachment of the stress fibres is managed through the ERM proteins (ezrin, radixin, moesin). These bifunctional proteins bind through their N-terminal part to transmembrane proteins (CD44 or ICAM proteins) and interact through their C-terminal part with the actin filaments. This interaction is essential for Rho-governed cytoskeletal changes.

All three subfamilies are monoglucosylated by *C. difficile* toxins (91, 92). In fact, toxins A and B catalyse the incorporation of glucose moiety into Thr 37 of RhoA or Thr 35 of both Rac and Cdc42 (88, 94). This modification renders Rho, Rac and Cdc42 inactive, thereby losing their properties to induce actin polymerisation and filament bundling. Inhibition of these GTPases causes the shut-down of signal transduction cascades leading to: (i) depolymerisation of the cytoskeleton; (ii) gene transcription of certain stress-activated protein kinases; (iii) a drop in synthesis of phosphatidylinositol 4,5 biphosphate; (iv) and possibly even the loss of cell polarity. By inhibition of signal transduction cascades, toxins A and B are able to block downstream responses (95–99).

Recently, it has been reported that intestinal cells exposed to *C. difficile* toxins A and B exhibit typical features of apoptosis in that a significant proportion of the toxin exposed cells shows nuclear fragmentation and chromatin condensation (100–103). The inhibition of proteins belonging to the Rho family due to *C. difficile* toxins seems to play a role in the induction of apoptosis in intestinal cells.

It has also been demonstrated that toxin B is a potent activator of human monocytes and toxin A is a potent chemoattractant of granulocytes (104, 105).

Hence, toxin B, shown to be extremely toxic for monocytes, initially induces the secretion of proinflammatory products (IL1, IL6, TNF) contributing to epithelium damage, fluid secretion, mucus release and membrane permeability and then eliminates the monocytes, thus preventing phagocytosis of the bacteria.

It has been demonstrated that toxin A causes a rapid dose-dependant increase of free cytosolic calcium in human granulocytes that stimulates cytokine release from macrophages *in vitro* and may be a mediator in eliciting chemotactic response.

Furthermore, a recent study provided indications of IL8 production in T84 and HT29 cells after exposure to toxin A (103). In particular, it has been demonstrated that cultured, as well as primary human colonic epithelial cells, undergo apoptosis following cell rounding and detachment, and then produce IL8.

As IL8 is a potent chemoattractant for polymorphonuclear cells its production may be pivotal in the induction of the intestinal inflammation seen in pseudomembranous colitis.

All these results certainly demonstrate that these two exotoxins represent the major virulence factors produced by *C. difficile* (46, 106), even if other putative virulence determinants (107) could play an important role in its pathogenicity.

CLOSTRIDIUM PERFRINGENS ENTEROTOXIN

Clostridium perfringens is an ubiquitous anaerobic, spore-forming, gram-positive bacterium resident in human gut and associated to gastrointestinal disorders since 1895 by the German microbiologist E. Klein. However, the first episode of food poisoning caused by *C. perfringens* involving about 250 people was described only several decades later, in 1943, by English epidemiologists. This common foodborne illness (108) is caused by the ingestion of foods contaminated with very high concentrations (> 10⁵ bacteria/g) of type A vegetative cells. The production of toxin in the digestive tract (or *in vitro*) is associated with bacterial sporulation.

C. perfringens enterotoxin (109) is a single polypeptide chain with a molecular weight of 35 kDa, eliciting a cytotoxic activity on intestinal cells. The primary subcellular target of the toxin should be represented by the cell membrane as recently demonstrated by us also for *C. perfringens* epsilon toxin (unpublished data). The following steps should characterise the cytotoxic activity:

- (i) Enterotoxin binding to a 50 kDa protein receptor present on the membrane;

- (ii) Modification of the toxin-receptor complex of about 90 kDa after interaction with a membrane protein of 70 kDa and following establishment of a larger molecular complex of about 160 kDa;
- (iii) Consequent structural and functional damages on cell membrane resulting from pore formation due to the partial membrane insertion of the large 160 kDa complex containing the toxin (110).

The major repercussions of membrane damage on intestinal physiology are the inhibition of amino acid transport and the increased secretion of sodium chloride.

ENTEROCOCCUS FAECALIS CYTOLYSIN

This toxin produced by 60% of clinical isolates of *E. faecalis* (111) is a heterodimeric polypeptide consisting of two different structural subunits which are both required for haemolytic and bactericidal activity (112). In fact, early reports on this cytolysin (113, 114) described its ability to inhibit the growth of gram-positive bacteria.

According to recent results (115) the toxin belongs to subgroup A lantibiotics which are elongated, amphiphilic peptides able to open voltage-dependent pores in the bacterial membrane, interfering with energy transduction and modifying membrane potential.

Because of the ability of the toxin to act against gram-positive bacteria, *E. faecalis* cytolysin-producing strains are expected to be able to protect themselves but the mechanism by which immunity is achieved is not definitively understood (116). Recent results seem to demonstrate, however, that immunity arises from a single open reading frame at the 3' end of the cytolysin operon and that the immunity gene is co-transcribed with the gene encoding the extracellular cytolysin activator (117, 118). In fact, the cytolysin is encoded by large, pAD1-type, pheromone-responsive plasmids and the genetic organisation of the pAD1 operon has been elucidated by transposon insertional mutagenesis, followed by intracellular and extracellular complementation (112, 119).

The *E. faecalis* cytolysin is the only lantibiotic described so far which is also toxic for mammalian cells.

Furthermore, this toxin has been demonstrated to significantly contribute to the severity and lethality of enterococcal infection in three animal models (120–123) as well as in humans (111, 124, 125).

ENTEROTOXIGENIC ESCHERICHIA COLI CYTOTOXINS

Enterotoxigenic *Escherichia coli* (ETEC) are among the most relevant causes of diarrhoea. ETEC are known to produce 4 cytotoxin types: the heat-labile (LT1 and LT2) and the heat-stable (STa and STb) enterotoxins, the cytotoxic necrotising factors (CNF1 and CNF2) and the cytolethal distending toxins (CDTs).

E. COLI HEAT-LABILE ENTEROTOXINS (LTs)

LT1 enterotoxin is closely related to cholera toxin (CT), sharing 80% sequence identity with the A and B subunits of CT (126). LT1, like CT, is an A-B subunit toxin (A/B ratio, 1/5) where B is the subunit (11.6 kDa) binding the GM1 ganglioside receptor and A is the enzymatic intracellular acting component. The A subunit consists of two components generated by proteolysis. A1 (21.8 kDa) is an ADP-ribosyltransferase and A2 (5.4 kDa) links A1 to the B subunits. X-ray crystallography shows that the structure of LT1 consists of 5 B subunits constituting a pentamer with a central pore, where the carboxy terminus of A2 is located. A2 is linked, by an alpha helix, to the A1 subunit (127). The A1 subunit ADP-ribosylates the Gs alpha chain of a heterotrimeric GTP-binding protein which controls the activity of adenylate cyclase (Gs). ADP-ribosylation of alpha Gs by LT1/CT occurs only in the presence of the small GTP-binding protein ARF and leads to the inhibition of the GTPase activity of alpha Gs (128). This provokes the intracellular activation of adenylate cyclase with consequent elevation of cyclic AMP. Like CT, LT1 enters cells by endocytosis and is transferred from early endosomes to late endosomes where, apparently, the separation between the A1 and the A2/B5 subunits occurs. The A1 subunit is therefore transferred from late endosomes to the trans-Golgi network and, in a retrograde fashion, to the endoplasmic reticulum from where it escapes into the cytosol. The enzymatic moiety of LT1 is thus delivered directly at the cell baso-lateral pole where the Gs alpha subunits are located. The A2/B5 fragment ends in lysosomes where it is degraded (129).

Elevation of cAMP by LT1 activates a cAMP dependent kinase (A-kinase) which up-regulates chloride secretion by phosphorylation of the chloride channel CFTR. However, LT1 activity on intestinal cells may induce others effects. Elevating cAMP levels, LT1 also increases the production of platelet activating factor (PAF), which in turn, stimulates production of prostaglandins PGE1 and PGE2 of the E series (130, 131). Despite the similarity with CT, in terms of receptor binding and enzymatic activity, LT1-producing *E. coli* induce mild disease compared to CT. Like CT, LT1 may also alter the activity of the enteric nervous system. Serotonin (5-HT) and VIP are released into the lumen of the small bowel *in vivo* after treatment with CT (132). There is some evidence that CT (thus probably LT1) can bind and activate VIP-containing neurons in the intestinal sub-mucosa of guinea pigs (133).

LT2 has been isolated essentially from animals. It shares only 55% identity with the A subunit of CT but essentially no homology with the B subunit of CT (134). LT2 can be divided into two subgroups, LT2a and LT2b, on the basis of their amino acid sequences. The LT2 subunit B does not bind to GM1 gangliosides; LT2a preferentially binds to GD1b gangliosides and LT2b to GD1a gangliosides.

***E. COLI* HEAT STABLE ENTEROTOXINS (STs)**

This family of enterotoxins encompasses 2 main members: STa and STb. STa is a cystein-rich peptide of 18 amino-acids (aa), encoded by the transposon-associated *estA* gene located on a plasmid (135). STa residues from 5 to 17 allow full binding to its receptor and enterotoxic activities. STa binds to a receptor, the guanylate cyclase (GC) (a 120 kDa protein), localised in the intestinal brush border membrane of the entire digestive tract. GC decreases from the small intestine to the rectum and is present in large amount in young children, rapidly dropping with increasing age (136). This may explain why STa-induced diarrhoea is more severe in young children than in adults. STa binding activates GC by changing GC conformation, thus inhibiting the kinase activity domain of GC. In fact, genetic deletion of the kinase domain provokes the permanent activation of GC and its unresponsiveness to STa. Activation of GC by STa increases the level of intracellular cyclic GMP which in turn stimulates chloride secretion. This results in the inhibition of NaCl absorption. Activation of chloride secretion may occur via activation of a cGMP-dependent kinase present in the apical membrane of enterocytes which ultimately activates the chloride channel CFTR. It has been reported that the secretory response to STa involves F-actin rearrangements only at the basal pole of T84 cells (137). STb, a 71 amino acid peptide, is plasmid encoded (*estB*) (138). The receptor for STb is still unknown. STb does not activate the guanylate cyclase and, consistent with the infrequent occurrence in human disease of *E. coli* strains expressing STb, seems to have no effect on human small intestine. In mouse intestine STb induces histological changes consisting of a loss of villus epithelial cells. No secretion of chloride has been detected. By acting via a pertussis toxin-sensitive heterotrimeric G-protein, STb stimulates a dose dependent increase in intracellular calcium (126).

***E. COLI* CYTOTOXIC NECROTISING FACTORS (CNFs)**

CNF1, discovered by Caprioli and colleagues (139) as a cell-associated product of *E. coli* strains isolated from young children with diarrhoea (140), causes necrosis of rabbit skin and multinucleation of different types of tissue cultured cells (141–150). A second type of CNF (CNF2) was then found in extracts of certain *E. coli* strains isolated from calves with enteritis (151). CNF1 and CNF2 are immunologically related (152, 153) and similar in apparent molecular weight (110–115 kDa). CNF1 which is also produced by *E. coli* strains isolated from animals (154, 155), is chromosomally encoded in a 620 Kb pathogenicity island (PAI II) containing (156) the η -hemolysin and a fimbrial gene (*prs*). CNF2 gene is located on a large transmissible F-like plasmid (Vir). CNF1 and CNF2 are encoded by a single structural gene. Analysis of the de-

duced amino acid sequences of CNF1 and CNF2 shows that the two toxins are quite similar (85% identical and 99% conserved residues over 1014 amino acids). Additionally, CNFs are predicted to have a relatively hydrophobic transmembrane domains overlapping partially two predicted helices and no classical signal peptide sequence is found in 50 N-terminal residues. At least for CNF1, it has been reported that the C-terminal part (30 kDa) is responsible for the catalytic activity of the toxin while the N-terminal part comprises the portion involved in cell receptor binding (157, 158). At the level of mRNA, the region corresponding to the first 48 codons of *cnf1* is involved in the translational regulation of CNF1 synthesis (158). CNFs share regions of homologous amino acids with two other bacterial toxins: *Pasteurella multocida* toxin (PMT) and the dermonecrotic toxin of *Bordetella pertussis* (DNT). CNFs, PMT and DNT form the new family of dermonecrotic toxins (157).

CNF1 is able to provoke a remarkable reorganisation of F-actin structures in cultured cells (159, 160). This toxin induces intense formation of stress fibers, focal contacts, membrane folding and retraction fibers. Reorganisation of the F-actin cytoskeleton by CNF1 results in the inability of the cells to undergo cytokinesis, giving rise to extremely flat large multinucleated cells. CNF1 induces actin reorganisation (161) by stimulating permanently the Rho protein. The first hint for this activity was observed as follows: when the cytosol from HEP-2 cells previously incubated with CNF1 was ADP-ribosylated with exoenzyme C3 it was observed that the Rho protein displayed a shift of molecular weight to a slightly higher value. This result indicated a possible post-translational modification of the GTP-binding protein in CNF1 treated cells (162) which occurred directly *in vitro* without the need of cellular co-factors. Microsequencing of CNF1-modified Rho showed a single modification in the CNF1-treated GTPase compared to wild type, Rho glutamine 63 changing into a glutamic acid (163). Therefore, CNF1 exerts a specific deamidase activity on Rho glutamine 63 (164). The equivalent amino acid of Rho glutamine 63 in p21 Ras is glutamine 61. An identical activity for CNF1 on Rho has been reported using mass spectrometry (165). Rho glutamine 63 is known to be an important residue for the intrinsic and RhoGAP mediated GTPase of Rho (166). Mutated Rho on glutamine 63 into glutamic acid (RhoQ63E) exhibits a mobility shift, upon electrophoresis, identical to CNF1-treated Rho. CNF1-treated Rho and RhoQ63E nucleotide dissociation rate is increased by 2 orders of magnitude but the RhoGAP activity is totally impaired on both CNF1-treated Rho and RhoQ63E. Thus, CNF1 allows Rho to be permanently bound to GTP, thereby enhancing the activity on Rho effectors. The Rho family of small GTPases encompasses three subfamilies that are differently involved in the regulation of the actin cytoskeleton. The Rho subfamily induces stress

fibre assembly, Rac the ruffling activity and Cdc42 the filopodia extension (7). In addition to deamidation of the glutamine 63 in Rho (163, 165), the other members of the Rho family, Rac and Cdc42, are also activated by CNF1 in glutamine 61 (167). However, although CNF1 may trigger all the Rho proteins, the activation of Cdc42 and Rac does transiently occur at high concentrations of CNF1 (167), Rho being the preferential target of the toxin. CNF1 deamidase activity is borne by the 30 kDa carboxy-terminus end of the molecule, whereas the cell binding moiety of CNF1 is localised in the amino-terminus of the molecule (157, 158). By covalently activating the Rho proteins, CNF1 induces a number of actin-dependent phenomena in epithelial cells, such as contractility, cell spreading and the assembly of focal adhesion plaques (168, 169) as well as the formation of actin stress fibres and an intense and generalised ruffling activity (159). CNF1-induced ruffling is reminiscent of the ruffling elicited by invasive bacteria and is consistent with the ability of epithelial cells to exert macropinocytosis (170).

Treatment of HEP-2 cells with CNF1, for increasing lengths of time (from 4 to 72 h), induces an augmented ability of the cells to ingest latex beads (170). Macropinocytosis is totally blocked when CNF1 treated cells are incubated with the F-actin disrupting drug cytochalasin B, demonstrating clearly that the process is F-actin dependent. In addition, non-invasive bacteria such as *Listeria innocua* are found (170) to be as invasive as *L. monocytogenes* when incubated with HEP-2 cells pretreated with CNF1. Only *L. innocua* harboring a plasmid containing the listeriolysin gene was found to multiply in the cytoplasm of HEP-2 cells treated with CNF1, indicating that macropinocytosis of bacteria was associated with formation of vacuoles.

Incubation of intestinal T84 cells with CNF1 does not influence transepithelial resistance, suggesting that the barrier function and surface polarity are not affected by the toxin (171). Incubation of T84 cells with CNF1 induces F-actin accumulation and impaired PMNs transepithelial migration (in either the luminal-to-basolateral or the basolateral-to-luminal directions). Thus CNF1-activated Rho, by reorganising F-actin structures in intestinal epithelial cells, induces a decreased ability of PMNs to cross the epithelial barrier. Furthermore, CNF1 effaces intestinal cells microvilli allowing a better bacterial adherence and probably also an improved growth of microbes by impairing absorption of nutrients by microvilli.

Strictly correlated with the above mentioned ability to induce an aspecific phagocytic-like behaviour in epithelial cells is the capability of CNF1 to protect cells against apoptosis (172, 173). The significant inverse correlation between the two phenomena suggests that they might be part of a pathogenic mechanism used by bacteria. In the mechanism used by CNF1 to hinder apoptosis, proteins of the Bcl-2 family as well as the mitochondrial homeostasis

play a pivotal role. In fact, CNF1 is capable of reducing the mitochondrial membrane depolarisation induced by UVB and modulating the intracellular expression of some Bcl-2 related proteins. In particular, the amount of death antagonists, such as Bcl-2 and Bcl-X_L, increases following exposure to CNF1 while the amount of the death agonist Bax remains substantially unchanged (174). Bcl-2 family proteins as well as mitochondria play an essential role in apoptosis and they are linked to each other. By modulating the expression of proteins of Bcl-2 family (probably *via* Rho activation), CNF1 may operate on one of the main regulatory systems which drive a cell towards death or survival. Very recently, evidence that Rho-dependent cell spreading activated by CNF1 is also involved in the protection against apoptosis in epithelial cells has been reported (5). In addition to the impairment of nuclear fragmentation, CNF1 protects cells from the radiation-induced rounding up and detachment and improves the ability of cells to adhere to each other and to the extracellular matrix by modulating the expression of proteins related to cell adhesion. In particular, the expression of integrins such as α_5 , α_6 and α_v , as well as of some heterotypic and homotypic adhesion-related proteins such as the Focal Adhesion Kinase, E-cadherin, a and b catenins, is significantly increased in cells exposed to CNF1. Thus, the toxin-induced improvement of cell adhesion and promotion of Rho-dependent cell spreading are mechanisms clearly involved in hindering apoptosis in epithelial cells. This is in accordance with the recent opinion that cell spreading favours cell survival (175). A toxin inducing cell spreading without activating Rho, such as Cytochalasin B, is in fact ineffective in favouring cell survival. Thus, by inducing both phagocytosis and protection against apoptosis CNF1 might allow bacteria to invade epithelial cells and to prolong their survival to permit copious bacterial multiplication within them. Also, protection against apoptosis by CNF1 will allow cells to escape from their elimination by macrophages.

***E. COLI* CYTOLETHAL DISTENDING TOXINS (CDTs)**

Cytolethal distending toxins belong to an emerging toxin family whose members have been found in several unrelated bacterial species including: *E. coli*, *Shigella dysenteriae*, *Campylobacter* sp. and *Haemophilus ducreyi*. Three adjacent or slightly overlapping chromosomal genes (*cdtA*, *cdtB* and *cdtC*) encode A (27 kDa), B (29 kDa) and C (20 kDa) subunits of CDT (176). The biological activity of CDT on cultured cells consists of the induction of giant elongated cells (in CHO cells) and an inhibition of cell division at the G₂/M stage of the cell cycle. This mitotic block is irreversible and induces cell death after 3 to 5 days of toxin exposure. Recently, it has been reported that CDT-treated cells accumulate in late G₂, because of the

lack of cdc2 protein kinase dephosphorylation (177). CDT might therefore interfere with a cell transduction cascade, initiated in the S phase (during DNA replication), called DNA damage checkpoint. However, the nature of the CDT subunit inducing this effect and its exact molecular intracellular activity is still unknown (for a review see 178).

STAPHYLOCOCCUS AUREUS ENTEROTOXINS AND CYTOLYSINS

Staphylococcus aureus enterotoxins

S. aureus is a major cause of food-borne illness (179) due to the ingestion of one or more types of pre-formed enterotoxins. Furthermore, staphylococcal enterotoxins have been implicated in the pathogenesis of other diseases such as enteritis, septicaemia, skin infections and a few cases of toxic shock (180). Among the different *S. aureus* enterotoxins (SEs) described so far, five main types (A, B, C, D and E) have been serologically identified since the early 1970s. Thence, on the basis of some differences detected in minor epitopes, the serotype C has been further subdivided into subtypes C₁, C₂ and C₃ and the total number of enterotoxins increased to seven: SEA, SEB, SEC1, SEC2, SEC3, SED, SEE (181). All these toxins are small monomeric proteins with molecular weights ranging from 22 to 29 kDa, generally resistant to heat, acids and proteases.

On the basis of structural homology ranging from 30 to about 90%, two different groups (181–183) are recognised: i) enterotoxins A and E exhibiting higher than 90% homology constitute together with toxin D a strictly related group; ii) a second group is represented by enterotoxin B which shares a higher homology with toxins C₁, C₂ and C₃.

As far as the biological activity is concerned, their binding to enterocytes has been demonstrated (184) even though no damage at tissue level has yet been revealed. This apparent contradiction found a satisfactory explanation in the demonstration by Buxser and coworkers (185) that SEA bound to murine lymphocytes. In the early 1990s *S. aureus* enterotoxins were definitively recognised as superantigens (186) able to massively (5–25%) stimulate T cell proliferation (187); in fact, the only detectable tissue effect in the small intestine of patients is represented by the appearance of an abundant infiltration of lymphocytes. Furthermore, this strong polyclonal stimulation of cellular immune response by enterotoxins should be responsible for the observed massive release of lymphokines, including IL-2, IL-4, IFN and TNF. Staphylococcal enterotoxins are the most potent T-cell activators recognised so far, being able to act at very low concentrations (10⁻¹³–10⁻¹⁶ M) both in stimulation of lymphocytes and cytokine production (183). Studies of the effect of staphylococcal enterotoxins SEA, SEB and SEC on rat, dog and flounder intestine seem to indicate these toxins as inhibitors of

absorption and/or stimulators of intestinal secretion (188–190).

STAPHYLOCOCCUS AUREUS DELTA-TOXIN

Almost all *S. aureus* clinical isolates produce a small protein toxin with an estimated molecular weight of about 3 kDa, named delta-toxin. The amphipatic nature of this exotoxin, belonging to staphylococcal cytolysins, is the main support for the hypothesis that an association of six molecules of delta toxin could bring about a transmembrane pore lined by the hydrophilic faces of the monomers (191).

Although the specific contribution of this toxin to the pathogenesis of human diseases is still poorly understood, there are interesting data in the literature (192) indicating a possible role in intestinal disease. In fact, a rapid alteration in intestinal transport has been demonstrated in guinea pig ileum after toxin exposure (193, 194), a high concentration of toxin being able to modify the normal histology of the gut epithelium (195).

CONCLUSIONS

In conclusion, the overall data currently available on the mode of action of several protein toxins produced by common enteric bacteria could provide in our opinion a promising tool to explain how these toxins, acting separately or in a synergistical way, might severely impair both the actin cytoskeleton and the intercellular tight junctions as well as alter intestinal permeability and damage or even destroy (46, 196) enterocytes and microvilli.

ACKNOWLEDGEMENTS

This review has been carried out with financial support from the Commission of the European Communities, Agriculture, and Fisheries (FAIR), specific RTD programme PL98-4230 'Intestinal Flora: Colonization Resistance and Other effects'. It does not reflect its views and in no way anticipates the Commission's future policy in this area.

The careful assistance of Donatella Lombardi in preparation of the manuscript is gratefully acknowledged.

REFERENCES

1. Aktories K. Rho proteins: targets for bacterial toxins. Trends Microbiol 1997; 5: 282–8.
2. Boquet P, Munro P, Fiorentini C, Just I. Toxins from anaerobic bacteria: specificity and molecular mechanisms of action. Curr Opin Microbiol 1998; 1: 66–74.
3. Donelli G, Fiorentini C. Cell injury and death caused by bacterial protein toxins. Toxicol Lett 1992; 64/65: 695–9.
4. Donelli G, Fiorentini C. Bacterial protein toxins acting on the cell cytoskeleton. Microbiologica 1994; 17: 345–62.
5. Fiorentini C, Gauthier M, Donelli G, Boquet P. Bacterial toxins and the rho GTP-binding protein: what microbes teach us about cell regulation. Cell Death Diff 1998; 5: 720–8.
6. Malorni W, Donelli G. Cell death: general features and morphological aspects. Ann NY Acad Sci 1992; 663: 218–33.

7. Hall A. Rho GTPases and the actin cytoskeleton. *Science* 1998; 279: 509–14.
8. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. *J Biochem (Tokyo)* 1996; 120: 215–28.
9. Ridley AJ. Rho: theme and variations. *Curr Biol* 1996; 6: 1256–64.
10. Tapon N, Hall A. Rho, Rac and CDC42 GTPases regulate the organization of the actin cytoskeleton. *Curr Opin Cell Biol* 1997; 9: 86–92.
11. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signalling networks. *Genes Dev* 1997; 11: 2295–322.
12. Berg RD. The indigenous gastrointestinal microflora. *Trends Microbiol* 1996; 4: 430–5.
13. Polk BF, Kasper DL. *Bacteroides fragilis* subspecies in clinical isolates. *Ann Intern Med* 1977; 86: 569–71.
14. Myers LL, Firehammer BD, Shoop DS, Border MM. *Bacteroides fragilis*: a possible cause of acute diarrhoeal disease in newborn lambs. *Infect Immun* 1984; 44: 241–4.
15. Myers LL, Shoop DS, Firehammer BD, Border MM. Association of enterotoxigenic *Bacteroides fragilis* with diarrhoeal disease in calves. *J Infect Dis* 1985; 152: 1344–7.
16. Obiso RJ Jr, Lyerly DM, Van Tassel RL, Wilkins TD. Proteolytic activity of the *Bacteroides fragilis* enterotoxin causes fluid secretion and intestinal damage *in vivo*. *Infect Immun* 1995; 63: 3820–6.
17. Myers LL, Shoop DS, Stackhouse LL, et al. Isolation of enterotoxigenic *Bacteroides fragilis* from humans with diarrhoea. *J Clin Microbiol* 1987; 25: 2330–3.
18. Van Tassel RL, Lyerly DM, Wilkins TD. Purification and characterization of an enterotoxin from *Bacteroides fragilis*. *Infect Immun* 1992; 60: 1343–50.
19. Moncrief JS, Obiso R Jr, Barroso LA, Kling JJ, Wright RL, Van Tassel RL, Lyerly DM, Wilkins TD. The enterotoxin of *Bacteroides fragilis* is a metalloprotease. *Infect Immun* 1986; 63: 175–81.
20. Franco AA, Mundy LM, Trucksis M, Wu S, Kaper JB, Sears CL. Cloning and characterization of the *Bacteroides fragilis* metalloprotease toxin gene. *Infect Immun* 1997; 65: 1007–13.
21. Kling JJ, Wright RL, Moncrief JS, Wilkins TD. Cloning and characterization of the gene for the metalloprotease enterotoxin of *Bacteroides fragilis*. *FEMS Microbiol Lett* 1997; 146: 279–84.
22. Sears CL, Myers LL, Lazenby A, Van Tassel RL. Enterotoxigenic *Bacteroides fragilis*. *Clin Infect Dis* 1995; 20 (suppl 2): S142–8.
23. Weikel CS, Grieco FD, Reuben J, Myers LL, Sack RB. Human colonic epithelial cells, HT29/C1, treated with crude *Bacteroides fragilis* enterotoxin dramatically alter their morphology. *Infect Immun* 1992; 60: 321–7.
24. Pantosti A, Cerquetti M, Colangeli R, D'Ambrosio F. Detection of intestinal and extra-intestinal strains of enterotoxigenic *Bacteroides fragilis* by the HT-29 cytotoxicity assay. *J Med Microbiol* 1994; 41: 191–6.
25. Koshy SS, Montrose MH, Sears CL. Human intestinal epithelial cells swell and demonstrate actin rearrangement in response to the metalloprotease toxin of *Bacteroides fragilis*. *Infect Immun* 1996; 64: 5022–8.
26. Saidi RF, Sears CL. *Bacteroides fragilis* toxin rapidly intoxicates human intestinal epithelial cells (HT29/C1) *in vitro*. *Infect Immun* 1996; 64: 5029–34.
27. Donelli G, Fabbri A, Fiorentini C. *Bacteroides fragilis* enterotoxin induces cytoskeletal changes and surface blebbing in HT-29 cells. *Infect Immun* 1996; 64: 113–9.
28. Chambers FG, Koshy SS, Saidi RF, Clark DP, Moore RD, Sears CL. *Bacteroides fragilis* toxin exhibits polar activity on monolayers of human intestinal epithelial cells (T84 cells) *in vitro*. *Infect Immun* 1997; 65: 3561–70.
29. Obiso RJ Jr, Azghani AO, Wilkins TD. The *Bacteroides fragilis* toxin fragilysin disrupts the paracellular barrier of epithelial cells. *Infect Immun* 1997; 65: 1431–9.
30. Wu S, Lim KC, Huang J, Saidi RF, Sears CL. *Bacteroides fragilis* enterotoxin cleaves the zonula adherens protein, E-cadherin. *Proc Natl Acad Sci* 1998; 95: 14979–84.
31. Bartlett JC. *Clostridium difficile*: history of its role as an enteric pathogen and the current state of knowledge about the organism. *Clin Infect Dis* 1994; 18 (suppl.4): S265–72.
32. Bartlett J, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. *N Engl J Med* 1978; 298: 531–4.
33. Borriello SP. *Clostridium difficile* and its toxin in the gastrointestinal tract in health and disease. *Res Clin Forums* 1979; 1: 33–5.
34. Fekety R. Guidelines for the diagnosis and management of *Clostridium difficile*-associated diarrhoea and colitis. *Am J Gastroenterol* 1997; 92: 739–50.
35. George RH, Symonds JM, Dimock F, et al. Identification of *Clostridium difficile* as a cause of pseudomembranous colitis. *Br Med J* 1978; 1: 695.
36. Gorbach SL, Bartlett JG. Anaerobic infections. *N Engl J Med* 1974; 290: 1177–84.
37. Kelly CP, Pothoulakis C, LaMont JT. *Clostridium difficile* colitis. *N Engl J Med* 1994; 330: 257–62.
38. Larson HE, Price AB, Honour P, Borriello SP. *Clostridium difficile* and the aetiology of pseudomembranous colitis. *Lancet* 1978; 1: 1063–6.
39. Lyerly DM, Barroso LA, Wilkins TD, Depitre C, Corthier G. Characterization of a toxin A-negative, toxin B-positive strain of *Clostridium difficile*. *Infect Immun* 1992; 60: 4633–9.
40. Lyerly DM, Wilkins TD. *Clostridium difficile*. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant EL, eds. *Infections of the gastrointestinal tract*. New York: Raven Press, 1995: 867–91.
41. Borriello SP, Davies HA, Kamiya S, Reed PJ. Virulence factors of *Clostridium difficile*. *Rev Infect Dis* 1990; 12 (Suppl. 2): 185–91.
42. Borriello SP, Wren BW, Hyde S, et al. Molecular, immunological, and biological characterization of the toxin A-negative, toxin B-positive strain of *Clostridium difficile*. *Infect Immun* 1992; 60: 4192–9.
43. Karjalainen T, Poilane I, Collignon A, et al. *Clostridium difficile* virulence: correlation between toxigenicity, enzyme production and serogroup. *Microecol Ther* 1995; 25: 157–63.
44. Kato N, Ou CY, Kato H, et al. Identification of toxigenic *Clostridium difficile* by the Polymerase Chain Reaction. *J Clin Microbiol* 1991; 29: 33–7.
45. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effects of *Clostridium difficile* toxins given intragastrically to animals. *Infect Immun* 1985; 47: 349–52.
46. Mastrantonio P, Pantosti A, Cerquetti M, Fiorentini C, Donelli G. *Clostridium difficile*: an update on virulence mechanisms. *Anaerobe* 1996; 2: 337–43.
47. Miller PD, Pothoulakis C, Baeker TR, LaMont JT, Rothstein TL. Macrophage-dependant stimulation of T cell-depleted spleen cells by *Clostridium difficile* toxin A and calcium ionophore. *Cell Immunol* 1990; 126: 155–63.
48. Moore H, Pothoulakis C, LaMont JT, Carlson S, Madara JL. *C. difficile* toxin A increases intestinal permeability and induces C1-secretion. *Am. J. Physiol.* 259: G165–72.

49. Seddon SV, Hemingway I, Borriello SP. Hydrolytic enzyme production by *Clostridium difficile* and its relationship to toxin production and virulence in the hamster model. *J Med Microbiol* 1990; 31: 169–74.
50. Torres JF. Purification and characterization of toxin B from a strain of *Clostridium difficile* that does not produce toxin A. *J Med Microbiol* 1991; 35: 40–4.
51. Torres JF, Jennische E, Lange S, Lonroth I. Enterotoxins from *Clostridium difficile*: diarrhoeogenic potency and morphological effects in the rat intestine. *Gut* 1990; 31: 781–5.
52. Banno Y, Kobayashi T, Kono H, Watanabe K, Ueno K, Nozawa Y. Biochemical characteristics and biologic action of two toxins (D-1 and D-2) from *Clostridium difficile*. *Rev Infect Dis* 1984; 6: S11–20.
53. Lima AA, Lysterly DM, Wilkins TD. Purification and characterization of toxins A and B of *Clostridium difficile*. *Infect Immun* 1988; 56: 582–8.
54. Sullivan NM, Pellet S, Wilkins TD. Purification and characterization of toxins A and B of *Clostridium difficile*. *Infect Immun* 1982; 35: 1032–40.
55. Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by *Clostridium difficile*. *Infect Immun* 1981; 34: 1036–43.
56. Donelli G, Fiorentini C, Mastrantonio P, Thelestam M. Cytotoxicity of *Clostridium difficile* toxin A on a rat intestinal cell line. In: Gopalakrishnakone P, Tan CK, eds. *Recent Advances in Toxinology Research*. National University of Singapore, 1992; 3: 401–6.
57. Fiorentini C, Paradisi S, Malorni W, et al. Cytoskeletal changes in cultured cells induced by toxin A from *Clostridium difficile*. *Microecol Ther* 1989; 18: 213–6.
58. Fiorentini C, Thelestam M. *Clostridium difficile* toxin A and its effects on cells. *Toxicon* 1991; 29: 543–67.
59. Malorni W, Paradisi S, Dupuis ML, Fiorentini C, Ramoni C. Enhancement of cell-mediated cytotoxicity by *Clostridium difficile* toxin A: an *in vitro* study. *Toxicon* 1991; 29: 417–28.
60. Pothoulakis C, Galili U, Castagliuolo I. A human antibody binds to a-galactose receptors and mimics the effects of *Clostridium difficile* toxin A in rat colon. *Gastroenterology* 1996; 110: 1704–12.
61. Pothoulakis C, Gilbert RJ, Cladaras C. Rabbit sucrase-isomaltase contains a functional intestinal receptor for *Clostridium difficile* toxin A. *J Clin Invest* 1996; 98: 641–9.
62. Pothoulakis C, LaMont JT, Eglow R. Characterizing of rabbit ileal receptors for *Clostridium difficile* toxin A. *J Clin Invest* 1991; 88: 119–25.
63. Gilbert RJ, Pothoulakis C, LaMont JT, Yakubovich M. *Clostridium difficile* toxin B activates calcium influx required for actin disassembly during cytotoxicity. *Am J Physiol* 1995; 268: G487–95.
64. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL. *Clostridium difficile* toxin B disrupts the barrier function of T84 monolayers. *Gastroenterology* 1992; 102: 416–23.
65. Barroso LA, Wang SZ, Phelps CJ, Hohnson JL, Wilkins TD. Nucleotide sequence of *Clostridium difficile* toxin B gene. *Nucleic Acids Res* 1990; 18: 4004.
66. Dove CH, Wang SZ, Price SB, et al. Molecular characterization of the *Clostridium difficile* toxin A gene. *Infect Immun* 1990; 58: 480–8.
67. Fluit ADC, Wolfhagen MJHM, Verdonk GPHT, Jansze M, Torensma R, Verhoef J. Nontoxigenic strains of *Clostridium difficile* lack the genes for both toxin A and toxin B. *J Clin Microbiol* 1991; 29: 2666–7.
68. Sauberborn M, von Eichel-Streiber C. Nucleotide sequence of *Clostridium difficile* toxin A. *Nucleic Acids Res* 1990; 18: 1629–30.
69. Von Eichel-Streiber C, Laufenberg-Feldmann R, Saringen S, Schulze J, Sauerborn M. Comparative sequence analysis of the *Clostridium difficile* toxins A and B. *Mol Gen Genet* 1992; 233: 260–8.
70. Krivan HC, Clark GF, Smith DF, Wilkins TD. Cell surface binding site for *Clostridium difficile* enterotoxin: evidence for a glycoconjugate containing the sequence Gal-1-3Gal-1-4GlcNAc. *Infect Immun* 1986; 53: 573–81.
71. Rolfe RD, Song W. Purification of a functional receptor for *Clostridium difficile* toxin A from intestinal brush border membranes of infant hamsters. *Clin Infect Dis* 1993; 16 (Suppl. 4): S219–27.
72. Tucker KD, Wilkins TD. Toxin A of *Clostridium difficile* binds to the human carbohydrate antigens I, X, and Y. *Infect Immun* 1991; 59: 73–8.
73. Lysterly DM, Barroso LA, Moncrief S, Wilkins TD. Molecular biology of toxins A and B of *Clostridium difficile*. *Microb Ecol Health Dis* 1995; 8: 186–7.
74. Mitchell TJ, Ketley JM, Haslam SC, et al. Effect of toxin A and toxin B of *Clostridium difficile* on rabbit ileum and colon. *Gut* 1986; 27: 78–85.
75. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT. Differential effect of *Clostridium difficile* toxin A and B on rabbit ileum. *Gastroenterology* 1987; 93: 273–9.
76. Riegler M, Sedivy R, Pothoulakis C, et al. *Clostridium difficile* toxin B is more potent than toxin A in damaging human colonic epithelium *in vitro*. *J Clin Invest* 1995; 95: 2004–11.
77. Guandalini S, Fasano A, Mastrantonio P, Pantosti A, Rubino A. Pathogenesis of post-antibiotic diarrhoea caused by *Clostridium difficile*: an *in vitro* study in the rabbit intestine. *Gut* 1988; 29: 598–602.
78. Fiorentini C, Arancia G, Paradisi S, et al. Effects of *Clostridium difficile* toxins A and B on cytoskeleton organization in Hep-2 cell: a comparative morphological study. *Toxicon* 1989; 27: 1209–18.
79. Fiorentini C, Chow SC, Mastrantonio P, Jeddi-Tehrani M, Thelestam M. *Clostridium difficile* toxin A induces multinucleation in the human leukemic T cell line JURKAT. *Eur J Cell Biol* 1992; 57: 292–7.
80. Fiorentini C, Falzano L, Rivabene R, Fabbri A, Malorni W. N-acetylcysteine protects epithelial cells against the oxidative imbalance due to *Clostridium difficile* toxins. *FEBS Lett* 1999; 453: 124–8.
81. Fiorentini C, Malorni W, Paradisi S, Giuliano M, Mastrantonio P, Donelli G. Interaction of *Clostridium difficile* toxin A with cultured cells: cytoskeletal changes and nuclear polarization. *Infect Immun* 1990; 58: 2329–36.
82. Florin I, Thelestam M. Lysosomal involvement in cellular intoxication with *Clostridium difficile* toxin B. *Microb Pathog* 1986; 1: 373–85.
83. Malorni W, Fiorentini C, Paradisi S, Giuliano M, Mastrantonio P, Donelli G. Surface blebbing and cytoskeletal changes induced *in vitro* by toxin B from *C. difficile*: an immunocytochemical and ultrastructural study. *Exp Mol Pathol* 1990; 52: 340–56.
84. Mitchell MJ, Laughon BE, Lin S. Biochemical studies on the effect of *Clostridium difficile* toxin B on actin *in vivo* and *in vitro*. *Infect Immun* 1987; 55: 1610–5.
85. Ottlinger M, Lin S. *Clostridium difficile* toxins B induces reorganization of actin, vinculin and talin in cultured cells. *Exp Cell Res* 1988; 174: 215–29.
86. Pothoulakis C, Barone LM, Ely R, et al. Purification and properties of *Clostridium difficile* cytotoxin B. *J Biol Chem* 1986; 261: 1316–21.

87. Thelestam M, Florin. Cytopathogenic action of *Clostridium difficile* toxins. *J Toxicol Toxin Rev* 1984; 3: 139–80.
88. Von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M. Large clostridial cytotoxins—a family of glycosyltransferases modifying small GTP-binding proteins. *Trends Microbiol* 1996; 4: 375–82.
89. Malorni W, Fiorentini C, Paradisi S, et al. Cell surface blebbing induced by toxin B from *C. difficile*: an *in vitro* study. *Microecol Ther* 1989; 18: 185–8.
90. Hofmann F, Busch C, Prepens U, Just I, Aktories K. Localization of the glucosyltransferase activity of *Clostridium difficile* toxin B to the N-terminal part of the holotoxin. *J Biol Chem* 1997; 272: 11074–8.
91. Just I, Wilm M, Selzer J, et al. The enterotoxin from *Clostridium difficile* (ToxA) monoglucosylates the Rho proteins. *J Biol Chem* 1995; 270: 13932–6.
92. Just I, Selzer J, Wilm M, Von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by *Clostridium difficile* toxin B. *Nature* 1995; 375: 500–3.
93. Sehr P, Joseph G, Genth H, Just I, Pick E, Aktories K. Glucosylation and ADP-ribosylation of Rho proteins—effects on nucleotide binding, GTPase activity, and effector-coupling. *Biochemistry* 1998; 37: 5296–304.
94. Pradel E, Parker CT, Schnaitman CA. Structures of the *rfaB*, *rfaI*, *rfaJ*, and *rfaS* genes of *Escherichia coli* K-12 and their roles in assembly of the lipopolysaccharide core. *J Bacteriol* 1992; 174: 4736–45.
95. Dillon ST, Rubin EJ, Yakubovich M, et al. Involvement of Ras-related Rho proteins in the mechanisms of action of *Clostridium difficile* toxin A and toxin B. *Infect Immun* 1995; 63: 1421–6.
96. Giry M, Popoff MR, von Eichel-Streiber C, Boquet P. Transient expression of RhoA, -B and -C GTPases in HeLa cells potentiates resistance to *Clostridium difficile* toxins A and B but not to *Clostridium sorfelli* lethal toxin. *Infect Immun* 1995; 63: 4063–71.
97. Just I, Fritz G, Aktories K, et al. *Clostridium difficile* toxin B acts on the GTP-binding protein Rho. *J Biol Chem* 1994; 269: 10706–12.
98. Just I, Richter HP, Prepens U, von Eichel-Streiber C, Aktories K. Probing the action of *Clostridium difficile* toxin B in *Xenopus laevis* oocytes. *J Cell Sci* 1994; 107: 1653–9.
99. Just I, Selzer J, Von Eichel-Streiber C, Aktories K. The low molecular mass GTP-binding protein Rho is affected by toxin A from *Clostridium difficile*. *J Clin Invest* 1995; 95: 1026–31.
100. Fiorentini C, Donelli G, Nicotera P, Thelestam M. *Clostridium difficile* toxin A elicits Ca²⁺ independent cytotoxic effects in cultured normal rat intestinal crypt cells. *Infect Immun* 1993; 61: 3988–93.
101. Fiorentini C, Fabbri A, Falzano L. Enterotoxins which induce apoptosis or protect against apoptosis in epithelial cells. In: Rampal P, Boquet P, eds. *Recent Advances in the Pathogenesis of Gastrointestinal Bacterial Infections*. 1998: 175–89.
102. Fiorentini C, Fabbri A, Falzano L, et al. *Clostridium difficile* toxin B induces apoptosis in intestinal cultured cells. *Infect Immun* 1998; 66: 2660–5.
103. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. Effect of *Clostridium difficile* toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. *Gut* 1996; 38: 337–47.
104. Flegel WA, Muller F, Daubener W, Fischer H-G, Haddin U, Norhoff H. Cytokine response by human monocytes to *Clostridium difficile* toxin A and toxin B. *Infect Immun* 1991; 59: 3659–66.
105. Pothoulakis C, Sullivan R, Melnick DA, et al. *Clostridium difficile* toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. *J Clin Invest* 1988; 81: 1741–5.
106. Haslam SC, Kettle JM, Mitchell TJ, Stephen J, Burdon DW, Candy DCA. Growth of *Clostridium difficile* and production of toxins A and B in complex and defined media. *J Med Microbiol* 1986; 21: 293–7.
107. Giuliano M, Piemonte F, Mastrantonio P. Production of an enterotoxin different from toxin A by *Clostridium difficile*. *FEMS Microbiol Lett* 1988; 50: 191–4.
108. Arcieri R, Dionisi AM, Caprioli A, et al. Direct detection of *Clostridium perfringens* enterotoxin in patients' stools during an outbreak of food poisoning. *FEMS Immunol Med Microbiol* 1999; 23: 45–8.
109. McClane BA. An overview of *Clostridium perfringens* enterotoxin. *Toxicon* 1996; 34: 1335–43.
110. Wiechowski EU, Kokai-Kun JF, McClane BA. Characterization of membrane-associated *Clostridium perfringens* enterotoxin following pronase treatment. *Infect Immun* 1998; 66: 5897–905.
111. Ike Y, Hashimoto H, Clewell DB. High incidence of hemolysin production by *Enterococcus (Streptococcus) faecalis* strains associated with human parenteral infections. *J Clin Microbiol* 1987; 25: 1524–8.
112. Gilmore MS, Segarra RA, Booth MC, Bogie CP, Hall LR, Clewell DB. Genetic structure of the *Enterococcus faecalis* plasmid pAD1-encoded cytolytic toxin system and its relationship to lantibiotic determinants. *J Bacteriol* 1994; 176: 7335–44.
113. Brock TD, Davie JM. Probable identity of a group D hemolysin with a bacteriocine. *J Bacteriol* 1994; 86: 708–12.
114. Brock TD, Peacher B, Pierson D. Survey of the bacteriocins of enterococci. *J Bacteriol* 1963; 86: 702–7.
115. Booth MC, Bogie CP, Sahl HG, Siezen RJ, Hatter KL, Gilmore MS. Structural analysis and proteolytic activation of *Enterococcus faecalis* cytolysin, a novel lantibiotic. *Mol Microbiol* 1996; 21: 1175–84.
116. Saris PE, Immonen T, Reis M, Sahl HG. Immunity to lantibiotics. *Antonie Leeuwenhoek* 1996; 69: 151–9.
117. Coburn PS, Hancock LE, Booth MC, Gilmore MS. A novel means of self-protection, unrelated to toxin activation, confers immunity to the bactericidal effects of the *Enterococcus faecalis* cytolysin. *Infect Immun* 1999; 67: 3339–47.
118. Segarra RA, Booth MC, Morales DA, Huycke MM, Gilmore MS. Molecular characterization of the *Enterococcus faecalis* cytolysin activator. *Infect Immun* 1991; 59: 1239–46.
119. Ike Y, Clewell DB, Segarra RA, Gilmore MS. Genetic analysis of the pAD1 hemolysin/bacteriocin determinant in *Enterococcus faecalis*: Tn917 insertional mutagenesis and cloning. *J Bacteriol* 1990; 172: 155–63.
120. Chow JW, Thal LA, Perri MB, et al. Plasmid-associated hemolysin and aggregation substance production contributes to virulence in experimental enterococcal endocarditis. *Antimicrob Agents Chemother* 1993; 37: 2474–7.
121. Ike Y, Hashimoto H, Clewell DB. Hemolysin of *Streptococcus faecalis* subspecies *zymogenes* contributes to virulence in mice. *Infect Immun* 1984; 45: 528–30.
122. Jett BD, Huycke MM, Gilmore MS. Virulence of enterococci. *Clin Microbiol Rev* 1994; 7: 462–78.
123. Jett BD, Jensen HG, Nordquist RE, Gilmore MS. Contribution of the pAD1-encoded cytolysin to the severity of experimental *Enterococcus faecalis* endophthalmitis. *Infect Immun* 1992; 60: 2445–52.
124. Huycke MM, Spiegel CA, Gilmore MS. Bacteremia caused by hemolytic, high level gentamicin-resistant *Enterococcus faecalis*. *Antimicrob Agents Chemother* 1991; 35: 1626–34.

125. Libertin CR, Dumitru R, Stein DS. The hemolysin/bacteriocin produced by enterococci is a marker of pathogenicity. *Diagn Microbiol Infect Dis* 1992; 15: 115–20.
126. Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. *Microbiol Rev* 1996; 60: 167–215.
127. Sixma TK, Pronk SE, Kalk KM, et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from *E. coli*. *Nature* 1991; 351: 371–7.
128. Moss J, Vaughan M. Activation of cholera toxin and heat-labile enterotoxins by ADP-ribosylation factors, a family of 20 kDa guanine nucleotide binding proteins. *Mol Microbiol* 1991; 5: 2621–7.
129. Majoul IV, Bastiaens PIH, Soling HM. Transport of an external lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. *J Cell Biol* 1996; 133: 777–89.
130. Guerrant RL, Fang GD, Thielman MH, Fonteles MC. Role of platelet activating factor (PAF) in the intestinal epithelial secretory and chinese hamster ovary (CHO) cell cytoskeletal responses to cholera toxin. *Proc Natl Acad Sci USA* 1998; 91: 9655–8.
131. Peterson JW, Ochoa LG. Role of prostaglandins and cAMP in the secretory effects of cholera toxin. *Science* 1989; 245: 857–9.
132. Nilsson O, Cassuto J, Larsson PA, et al. 5-hydroxy tryptamine and cholera secretion: a histochemical and physiological study in cats. *Gut* 1983; 24: 542–8.
133. Jiang MA, Kirchgessner A, Gershon MD, Surprenant A. Cholera toxin-sensitive neuron in Guinea-pig submucosal plexus. *Am J Physiol* 1993; 264: G86–94.
134. Pickett CL, Twiddy EM, Coker C, Holmes RA. Cloning, nucleotide sequence and hybridization studies of the type 2b heat-labile enterotoxin gene of *Escherichia coli*. *J Bacteriol* 1989; 171: 4945–52.
135. So M, McCarthy BJ. Nucleotide sequence of the bacterial transposon Tn 1681 encoding heat-stable (ST) toxin and its identification in enteropathogenic *Escherichia coli* strains. *Proc Natl Acad Sci USA* 1980; 77: 4011–5.
136. Cohen NB, Guarino A, Shulka R, Giannella RA. Age-related differences in receptors for *Escherichia coli* heat-stable enterotoxin in the small and large intestine of children. *Gastroenterology* 1988; 94: 367–73.
137. Matthews JB, Smith JA, Tally KJ, et al. Na⁺ K⁺ 2 Cl cotransport and Cl secretion evoked by heat-stable enterotoxin is microfilament dependent in T84 cells. *Am J Physiol* 1994; 265: G373–8.
138. Piken RM, Mazaitis AJ, Maas WK, Rey M, Heyneker H. Nucleotide sequences of the gene for heat-stable enterotoxin 2 of *Escherichia coli*. *Infect Immun* 1983; 42: 269–75.
139. Caprioli A, Falbo V, Roda LG, Ruggeri FM, Zona C. Partial purification and characterization of an *Escherichia coli* toxic factor that induces morphological cell alterations. *Infect Immun* 1983; 39: 1330–6.
140. Bisicchia R, Ciammarughi R, Caprioli A, Falbo V, Ruggeri FM. Toxin production and haemagglutination in strains of *Escherichia coli* from diarrhoea in Brescia, Italy. *J Hyg Camb* 1985; 95: 353–61.
141. Blanco J, Alonso MP, Gonzalez EA, Blanco M, Garabal JJ. Virulence factors of bacteraemic *Escherichia coli* with particular reference to production of cytotoxic necrotizing factor (CNF) by P-fimbriate strains. *J Med Microbiol* 1990; 31: 175–83.
142. Caprioli A, Donelli G, Falbo V, et al. A cell division-active protein from *E. coli*. *Biochem Biophys Res Commun* 1984; 118: 587–93.
143. De Rycke J, Mazars P, Nougayrede JP, et al. Mitotic block and delayed lethality in HeLa epithelial cells exposed to *Escherichia coli* BM2-1 producing cytotoxic necrotizing factor type 1. *Infect Immun* 1996; 64: 1694–705.
144. Donelli G, Fiorentini C. Cytotoxic necrotizing factors (*Escherichia coli*). In: Montecucco C, Rappuoli R, eds. *Guidebook to Protein Toxins and Their Use in Cell Biology*. Oxford: Oxford University Press, 1997: 69–71.
145. Donelli G, Fiorentini C, Falzano L, Fabbri A, Boquet P. *In vitro* studies of the mechanism of action of the cytotoxic necrotizing factor 1 from pathogenic *E. coli*. *Microecol Ther* 1995; 23: 107–10.
146. Donelli G, Fiorentini C, Falzano L, Pouchelet M, Oswald E, Boquet P. Effects induced by the cytotoxic necrotizing factor 1 (CNF1) from pathogenic *E. coli* on cultured epithelial cells. In: Witholt et al., eds. *Bacterial Protein Toxins*. *Zbl Bakt*, 1994; 24(suppl.): 60–71.
147. Falbo V, Famiglietti M, Caprioli A. Gene block encoding production of cytotoxic necrotizing factor 1 and hemolysin in *Escherichia coli* isolates from extraintestinal infections. *Infect Immun* 1992; 60: 2182–7.
148. Falbo V, Pace T, Picci L, Pizzi E, Caprioli A. Isolation and nucleotide sequence of the gene encoding cytotoxic necrotizing factor 1 of *Escherichia coli*. *Infect Immun* 1993; 61: 4909–14.
149. Falzano L, Fiorentini C, Boquet P, Donelli G. Interaction of *Escherichia coli* cytotoxic necrotizing factor type 1 (CNF1) with cultured cells. *Cytotechnology* 1993; 11(suppl.): 56–8.
150. Fiorentini C, Boquet P, Donelli G. Interaction of cytotoxic necrotizing factor type 1 (CNF1) from pathogenic *E. coli* with mammalian cells. *Microecol Ther* 1995; 25: 255–8.
151. De Rycke J, Guillot JF, Boivin R. Cytotoxins in non-enterotoxigenic strains of *Escherichia coli* isolated from feces of diarrheic calves. *Vet Microbiol* 1987; 15: 137–50.
152. Caprioli A, Falbo V, Ruggeri FM, et al. Cytotoxic necrotizing factor production by hemolytic strains of *Escherichia coli* causing extraintestinal infections. *J Clin Microbiol* 1987; 25: 146–9.
153. Caprioli A, Falbo V, Ruggeri FM, Minelli F, Orskov I, Donelli G. Relationship between Cytotoxic Necrotizing Factor production and serotype in hemolytic *Escherichia coli*. *J Clin Microbiol* 1989; 27: 758–61.
154. Caprioli A, Donelli G, Falbo V, Passi C, Pagano A, Mantovani A. Antimicrobial resistance and production of toxins in *Escherichia coli* strains from wild ruminants and the alpine marmot. *J Wildlife Dis* 1991; 27: 324–7.
155. Prada J, Baljer G, De Rycke JD, et al. Characteristics of alpha-hemolytic strains of *Escherichia coli* isolated from dogs with gastroenteritis. *Vet Microbiol* 1991; 29: 59–73.
156. Blum G, Falbo V, Caprioli A, Hacker J. Gene cluster encoding the cytotoxic necrotizing factor type 1 Prs fimbriae and a hemolysin from the pathogenicity island II of the uropathogenic *Escherichia coli* strain 96. *FEMS Microbiol Lett* 1995; 126: 189–96.
157. Lemichez E, Flatau G, Bruzzone M, Boquet P, Gauthier M. Molecular localization of the *Escherichia coli* cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. *Mol Microbiol* 1997; 24: 1061–70.
158. Fabbri A, Gauthier M, Boquet P. The 5' region of CNF1 harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell binding domain of the toxin. *Mol Microbiol* 1999; 33: 108–18.
159. Fiorentini C, Arancia G, Caprioli A, Falbo V, Ruggeri FM, Donelli G. Cytoskeletal changes induced on HEp-2 cells by the cytotoxic necrotizing factor (CNF) of *Escherichia coli*. *Toxicon* 1988; 26: 1047–56.

160. Fiorentini C, Donelli G, Matarrese P, Fabbri A, Paradisi S, Boquet P. *Escherichia coli* cytotoxic necrotizing factor 1: evidence for induction of actin assembly by constitutive activation of the p21 Rho GTPase. *Infect Immun* 1995; 63: 3936–44.
161. Matarrese P, Paradisi S, Fabbri A, Fiorentini C, Donelli G. A toxic factor from pathogenic *E. coli* strains enhances actin assembly in epithelial cultured cells. *J Exp Clin Cancer Res* 1995; 14: 78–9.
162. Oswald E, Sugai M, Labigne A, et al. Cytotoxic necrotizing factor type 2 produced by virulence *Escherichia coli* modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. *Proc Natl Acad Sci USA* 1994; 91: 3814–8.
163. Flatau G, Lemichez E, Gauthier M, et al. Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. *Nature* 1997; 387: 729–33.
164. Boquet P, Flatau G, Gauthier M, et al. Deamidation of Rho glutamine 63 by CNF1, a toxin inducing actin stress fiber formation. In: Hacker J et al., eds. *Bacterial Protein Toxins*. Zent bl Bakteriologie, 1998; suppl. 29: 175–83.
165. Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K. Gin 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. *Nature* 1997; 387: 725–9.
166. Rittinger K, Walker PA, Eccleston JF, Smerdon SJ, Gamblin SJ. Structure at 1.65 Angstrom of RhoA and its GTPase-activating protein in complex with transition state analog. *Nature* 1997; 389: 758–62.
167. Lerm M, Selzer J, Hoffmeyer A, Rapp UR, Aktories K, Schmidt G. Deamidation of Cdc42 and Rac by *Escherichia coli* cytotoxic necrotizing factor 1: activation of c-Jun N-terminal kinase in HeLa cells. *Infect Immun* 1999; 67: 496–503.
168. Fiorentini C, Fabbri A, Flatau G, et al. *Escherichia coli* cytotoxic necrotizing factor 1 (CNF1): a toxin which activates the rho GTPase. *J Biol Chem* 1997; 272: 19532–7.
169. Lacerda HM, Pullinger GD, Lax AJ, Rozenfurt E. Cytotoxic necrotizing factor 1 from *Escherichia coli* and dermonecrotic toxin from *Bordetella bronchiseptica* induce p21 Rho-dependent tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 cells. *J Biol Chem* 1999; 272: 9587–96.
170. Falzano L, Fiorentini C, Donelli G, et al. Induction of phagocytic behaviour in human epithelial cells by *E. coli* cytotoxic necrotizing factor type 1. *Mol Microbiol* 1993; 9: 1247–54.
171. Hofman P, Flatau G, Selva E, et al. *Escherichia coli* cytotoxic necrotizing factor 1 effaces microvilli and decreases transmigration of polymorphonuclear leukocytes in intestinal T84 epithelial cell monolayers. *Infect Immun* 1998; 66: 2494–500.
172. Fiorentini C, Fabbri A, Matarrese P, Falzano L, Boquet P, Malorni W. Hinderance of apoptosis and phagocytic behaviour induced by *Escherichia coli* cytotoxic necrotizing factor 1: two related activities in epithelial cells. *Biochem Biophys Res Comm* 1997; 241: 341–6.
173. Fiorentini C, Matarrese P, Straface E, et al. Toxin-induced activation of rho GTP-binding protein increases Bcl-2 expression and protects against apoptosis. *Exp Cell Res* 1998; 242: 341–50.
174. Fiorentini C, Matarrese P, Straface E, et al. Rho-dependent cell spreading activated by *E. coli* cytotoxic necrotizing factor 1 hinders apoptosis in epithelial cells. *Cell Death Diff* 1998; 5: 921–9.
175. Ruoslahti E. Stretching is good for a cell. *Science* 1997; 276: 1345–6.
176. Scott DA, Kaper JB. Cloning and sequencing of the genes encoding *Escherichia coli* cytolethal distending toxin. *Infect Immun* 1994; 62: 244–51.
177. Comayras C, Tasca C, Péres SY, Ducommun B, Oswald E, De Rycke J. *Escherichia coli* cytolethal distending toxin blocks the HeLa cell cycle at the G2/M transition by preventing cdc2 protein kinase dephosphorylation and activation. *Infect Immun* 1997; 65: 5088–95.
178. Pickett CL, Whitehouse CA. The cytolethal distending toxin family. *Trends Microbiol* 1999; 7: 292–7.
179. Tranter HS. Foodborne staphylococcal illness. *Lancet* 1990; 336: 1044–6.
180. Alouf JE, Knoll H, Kohler W. The family of mitogenic, shock-inducing and superantigenic toxins from staphylococci and streptococci. In: Alouf JE, Freer JG, eds. *Sourcebook of bacterial protein toxins*. London: Academic Press Ltd, 1991: 367–414.
181. Bergdoll MS. The role of the staphylococcal enterotoxins in staphylococcal disease. In: Falmagne P, Alouf JE, Fehrenbach FJ, Jeliaszewicz J, Thelestam M, eds. *Bacterial Protein Toxins*. Stuttgart: Gustav Fischer, Zent bl Bakteriologie, 1988; suppl. 15.
182. Johnson HM, Russell JK, Pontzer CH. Staphylococcal enterotoxin microbial superantigens. *FASEB J* 1991; 5: 2706–12.
183. Betley MJ, Mekalanos JJ. Staphylococcal enterotoxin A is encoded by phage. *Science* 1985; 229: 185–7.
184. Spero L, Johnson-Winger A, Schmidt JJ. Enterotoxins of Staphylococci. In: Hardegree CM, Tu AT, eds. *Handbook of Natural Toxins*. New York: Dekker, 1988: 131–63.
185. Buxser S, Bonventre PF, Archer DL. Specific receptor binding of staphylococcal enterotoxins by murin spleen lymphocytes. *Infect Immun* 1981; 33: 827–33.
186. James SP. Potential role of superantigens in gastrointestinal disease. *Gastroenterology* 1993; 105: 1569–71.
187. Fleischer B, Schrezenmeier H. T-cell stimulation by Staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex Class II molecules on accessory or target cells. *J Exp Med* 1988; 167: 1697–707.
188. Elias J, Shields R. Influence of staphylococcal enterotoxin on water and electrolyte transport in the small intestine. *Gut* 1976; 17: 527–35.
189. Huang KC, Chen TST, Rout WR. Effect of staphylococcal enterotoxins A, B, and C on ion transport and permeability across the flounder intestine. *Proc Soc Exp Biol Med* 1974; 147: 250–4.
190. Sullivan NM, Asano T. Effects of staphylococcal enterotoxin B on intestinal transport in the rat. *Am J Physiol* 1971; 220: 1793–7.
191. Bernheimer AW, Rudy B. Interactions between membranes and cytolytic peptides. *Biochim Biophys Acta* 1986; 864: 123–41.
192. Kapral FA. *Staphylococcus aureus* delta toxin as an enterotoxin. In: Evered D, Whelan J, eds. *Microbial toxins and diarrhoeal disease*. London: Pitman, 1985: 215–29.
193. Kapral FA, O'Brien AD, Ruff PD, Drugan Jr WJ. Inhibition of water absorption in the intestine by *Staphylococcus aureus* delta-toxin. *Infect Immun* 1976; 13: 140–5.
194. O'Brien AD, McCling HJ, Kapral FA. Increased tissue conductance and ion transport in guinea pig ileum after exposure to *Staphylococcus aureus* delta-toxin *in vitro*. *Infect Immun* 1978; 21: 102–13.

195. O'Brien AD, Kapral FA. Increased cyclic adenosine 3', 5'-monophosphate content in guinea pig ileum after exposure to *Staphylococcus aureus* delta-toxin. *Infect Immun* 1976; 13: 152–62.
196. Donelli G, Mastrantonio P. Bacterial virulence factors in inflammatory bowel disease. In: Caprilli R, ed. *Inflammatory Bowel Disease: Trigger Factors and Trends in Therapy*. Stuttgart: Schattauer, 1997: 25–34.